Cargando…

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

OBJECTIVE: To determine whether rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP) antibodies, or carriage of shared epitope (SE) and PTPN22 genetic susceptibility variants predict response to therapy in patients with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potter, C, Hyrich, K L, Tracey, A, Lunt, M, Plant, D, Symmons, D P M, Thomson, W, Worthington, J, Emery, P, Morgan, A W, Wilson, A G, Isaacs, J, Barton, A
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2009
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596303/ https://www.ncbi.nlm.nih.gov/pubmed/18375541 http://dx.doi.org/10.1136/ard.2007.084715

Ejemplares similares

Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients
por: Viatte, Sebastien, et al.
Publicado: (2012)

Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
por: Al-Shukaili, Ahmed, et al.
Publicado: (2012)

The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
por: van Damme, N, et al.
Publicado: (2002)

Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies
por: Farragher, Tracey M, et al.
Publicado: (2010)

Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis
por: Mewar, Devesh, et al.
Publicado: (2006)

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis
por: Taylor, Peter, et al.
Publicado: (2011)

Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides
por: de Siqueira, Marcelo Bogliolo Piancastelli, et al.
Publicado: (2015)

Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients
por: Sulaiman, Farah Nadiah, et al.
Publicado: (2019)

Rheumatoid factor versus anti - cyclic citrullinated peptide antibody as screening tool for rheumatoid arthritis in an ophthalmic clinic
por: Singh, Prabhakar, et al.
Publicado: (2020)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden
por: Kokkonen, Heidi, et al.
Publicado: (2007)

Erratum to: A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2012)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Plant, Darren, et al.
Publicado: (2012)

Correction: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden
por: Kokkonen, Heidi, et al.
Publicado: (2007)

Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis
por: Burr, Marian L, et al.
Publicado: (2012)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis
por: Yang, Xiaochun, et al.
Publicado: (2021)

Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis
por: Won, Pureun, et al.
Publicado: (2021)

Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis
por: Gonzalez-Lopez, Laura, et al.
Publicado: (2014)

Serious Infection Following Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis: Lessons From Interpreting Data From Observational Studies
por: Dixon, W G, et al.
Publicado: (2007)

Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
por: El-Banna, Hassan, et al.
Publicado: (2014)

Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies
por: Vignesh, Ammapati Paul Pandian, et al.
Publicado: (2015)

Anti-Cyclic Citrullinated Peptide Antibody and Periodontal Status in Rheumatoid Arthritis Patients
por: Mohamad, Wan Majdiah Wan, et al.
Publicado: (2018)

Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis
por: Mortazavi, Nazanin, et al.
Publicado: (2022)

Development of anti-citrullinated protein antibody and rheumatoid factor isotypes prior to the onset of rheumatoid arthritis
por: Bos, Wouter H, et al.
Publicado: (2014)

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
por: Hyrich, Kimme L., et al.
Publicado: (2011)

Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis
por: Fathi, Nihal A, et al.
Publicado: (2008)

Rethink About the Role of Rheumatoid Factor and Anti-citrullinated Protein Antibody in Rheumatoid Arthritis
por: Sung, Wang Yu, et al.
Publicado: (2021)

PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease
por: Johansson, Martin, et al.
Publicado: (2006)

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2007)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
por: Alexiou, Ioannis, et al.
Publicado: (2007)

Clinical significance of anti-cyclic citrullinated peptide antibodies in patients with juvenile rheumatoid arthritis
por: Bo, Li, et al.
Publicado: (2008)

The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients
por: Jearn, La-He, et al.
Publicado: (2010)

Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis
por: Abdul Wahab, Asrul, et al.
Publicado: (2013)

Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis
por: Shibahara, Tomoya, et al.
Publicado: (2016)

The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis
por: Lv, Qianwen, et al.
Publicado: (2014)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b2vtlm98rv3hkv42ljjt2u65jd